View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Technology
  2. Software
August 14, 2014

How Intel plans to fight Parkinson’s disease with big data

Intel has partnered with the Michael J. Fox Foundation for Parkinson's Research to use big data analytics and data from wearable computing to fight the disease.

By CBR Staff Writer

Intel has partnered with the Michael J. Fox Foundation for Parkinson’s Research to develop an app and wearable device that will analyse and track those who suffer from Parkinson’s disease.

The collaboration will include research studies using a big data analytics platform that will collect information regarding the patient using wearable technology.

The wearable device will be accompanied by an app that will enable patients to record the medications they take, as well as recording their current condition.

Intel hopes that the data produced by the wearable technology will help improve the treatment and research of the disease as well.

Intel Data Center Group senior VP and GM, Diane Bryant, said: "The variability in Parkinson’s symptoms creates unique challenges in monitoring progression of the disease.

"Emerging technologies can not only create a new paradigm for measurement of Parkinson’s, but as more data is made available to the medical community, it may also point to currently unidentified features of the disease that could lead to new areas of research.

Content from our partners
Unlocking growth through hybrid cloud: 5 key takeaways
How businesses can safeguard themselves on the cyber frontline
How hackers’ tactics are evolving in an increasingly complex landscape

The Michael J. Fox Foundation CEO, Todd Sherer, said: "Nearly 200 years after Parkinson’s disease was first described by Dr. James Parkinson in 1817, we are still subjectively measuring Parkinson’s disease largely the same way doctors did then.

"Data science and wearable computing hold the potential to transform our ability to capture and objectively measure patients’ actual experience of disease, with unprecedented implications for Parkinson’s drug development, diagnosis and treatment."

Websites in our network
Select and enter your corporate email address Tech Monitor's research, insight and analysis examines the frontiers of digital transformation to help tech leaders navigate the future. Our Changelog newsletter delivers our best work to your inbox every week.
  • CIO
  • CTO
  • CISO
  • CSO
  • CFO
  • CDO
  • CEO
  • Architect Founder
  • MD
  • Director
  • Manager
  • Other
Visit our privacy policy for more information about our services, how New Statesman Media Group may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
THANK YOU